Lonza Group AG, CH0013841017

Lonza Group AG, CH0013841017

12.09.2022 - 07:04:05

Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division

About Lonza Lonza is a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare industry.

Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With more than 17,000 employees (full-time equivalent), we comprise high-performing teams and individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 3 billion with a CORE EBITDA of CHF 987 million in H1 2022. Find out more at www.lonza.com

Follow @Lonza on LinkedIn Follow @LonzaGroup on Twitter

Lonza Contact Details

Victoria Morgan Head of External Communications Lonza Group Ltd Tel +41 61 316 2283victoria.morgan@lonza.com

Lyle Wheeler Investor Relations Lonza Group Ltd Tel +41 79 154 9522lyle.wheeler@lonza.com

End of Media Release

Language: English Company: Lonza Group AG M?nchensteinerstrasse 38 4052 Basel

Switzerland Phone: +4161 316 81 11 Internet: www.lonza.com ISIN: CH0013841017 Valor: 1384101 Listed: SIX Swiss Exchange EQS News ID: 1439795 ? End of News EQS News Service

1439795??12.09.2022?CET/CEST

@ dgap.de